Viscodyne-D Uses

• Viscodyne-D indications
• Uses of Viscodyne-D in details
• Viscodyne-D description
• Viscodyne-D dosage
• Viscodyne-D interactions
• Viscodyne-D side effects
• Viscodyne-D contraindications

What is Viscodyne-D?

Viscodyne-D is an antihistamine that reduces the effects of natural chemical histamine in the body. Histamine can produce symptoms of sneezing, itching, watery eyes, and runny nose.

Viscodyne-D is used to treat cold or allergy symptoms such as sneezing, itching, watery eyes, or runny nose.

Viscodyne-D is also used to treat itching and swelling caused by chronic urticaria (hives).

Viscodyne-D may also be used for purposes not listed in this medication guide.

Viscodyne-D indications

Perennial Allergic Rhinitis : Viscodyne-D

Oral Solution, USP is indicated for the relief of symptoms associated with perennial allergic rhinitis due to allergens such as dust mites, animal dander and molds in children 6 to 23 months of age. Symptoms treated effectively include sneezing, rhinorrhea, postnasal discharge, nasal pruritus, ocular pruritus, and tearing.

Chronic Urticaria: Viscodyne-D

Oral Solution, USP is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in children 6 months to 5 years of age. It significantly reduces the occurrence, severity, and duration of hives and significantly reduces pruritus.

How should I use Viscodyne-D?

Use Viscodyne-D as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Do not remove the blister unit from the carton until you are ready to take Viscodyne-D. Make sure that your hands are dry when you open the blister unit. Do not push the tablet through the foil. Peel back the foil on the blister unit and place the tablet on your tongue. The tablet dissolves quickly and can be swallowed with saliva. Viscodyne-D may be taken with or without water. Take the tablet immediately after opening the blister unit. Do not store the removed tablet for future use.
• If you miss a dose of Viscodyne-D and you are taking it regularly, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Viscodyne-D.

Uses of Viscodyne-D in details

Use: Labeled Indications

Oral:

Allergic rhinitis: Relief of symptoms associated with allergic rhinitis.

Urticaria, chronic spontaneous: Treatment of uncomplicated skin manifestations of chronic spontaneous urticaria.

Injection:

Urticaria, acute: Treatment of acute urticaria.

Off Label Uses

Anaphylaxis (adjunct to epinephrine for relief of cutaneous symptoms)

Based on joint guidelines from the American Academy of Allergy, Asthma & Immunology, American College of Allergy, Asthma & Immunology, and Joint Council of Allergy, Asthma and Immunology on the diagnosis and management of anaphylaxis and guidelines from the World Allergy Organization on anaphylaxis, Viscodyne-D may be used as adjunctive treatment, although should not be used as monotherapy or as first-line therapy of anaphylaxis.

Angioedema, acute allergic or recurrent idiopathic

Clinical experience suggests the utility of second-generation H receptor antagonists (eg, Viscodyne-D) for the treatment of acute allergic or recurrent idiopathic angioedema.

Viscodyne-D description

Viscodyne-D HCl is a piperazine derivative and a metabolite of hydroxyzine. It competes reversibly with histamine to block the histamine (H₁) receptor sites. Viscodyne-D HCl is considered a long-acting nonsedating antihistamine and has some mast-cell stabilizing activity.

Viscodyne-D dosage

Viscodyne-D

Oral Solution, USP can be taken without regard to food consumption.

Children 2 to 5 Years for Chronic Urticaria: The recommended initial dose of Viscodyne-D

Oral Solution, USP in children aged 2 to 5 years is 2.5 mg (½ teaspoonful) syrup once daily. The dosage in this age group can be increased to a maximum dose of 5 mg per day given as 1 teaspoonful syrup once a day, or one ½ teaspoonful syrup given every 12 hours.

Children 6 months to < 2 years for Perennial Allergic Rhinitis and Chronic Urticaria: The recommended dose of Viscodyne-D

Oral Solution, USP in children 6 months to 23 months of age is 2.5 mg (½ teaspoonful) once daily. The dose in children 12 to 23 months of age can be increased to a maximum dose of 5 mg per day, given as ½ teaspoonful (2.5 mg) every 12 hours.

Viscodyne-D interactions

See also:
What other drugs will affect Viscodyne-D?

Theophylline decreases the clearance of Viscodyne-D although the disposition of theophylline is not affected.

In common with other antihistamines it is recommended that excessive alcohol consumption be avoided. Concurrent use of Viscodyne-D with other CNS depressants should also be avoided as reduction in alertness and impairment of performance may occur.

No evidence of interactions with antipyrine, azithromycin, cimetidine, diazepam, erythromycin, ketoconazole and pseudoephedrine has been reported.

Viscodyne-D side effects

See also:
What are the possible side effects of Viscodyne-D?

The following clinically significant adverse reaction is described elsewhere in the labeling:

• Somnolence/Sedation

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Oral Viscodyne-D

The following adverse reactions associated with the use of oral Viscodyne-D were identified in clinical trials.

In clinical trials in patients 12 years and older the most common adverse reactions to oral Viscodyne-D occurring with a 2% or greater incidence and greater than placebo were somnolence (14%), fatigue (6%), dry mouth (5%), pharyngitis (2%), and dizziness (2%). In clinical trials in children 6 to 11 years of age with oral Viscodyne-D the most common adverse reactions occurring with a 2% or greater incidence and greater than placebo were headache, pharyngitis, abdominal pain, coughing, somnolence, diarrhea, epistaxis, bronchospasm, nausea, and vomiting. Somnolence appeared to be dose related. Adverse reactions reported in placebo-controlled trials with oral Viscodyne-D in pediatric patients 2 to 5 years were qualitatively similar in nature and generally similar in frequency to those reported in trials with children 6 to 11 years of age. In placebo-controlled trials of pediatric patients 6 to 24 months of age, the incidences of adverse experiences were similar in the oral Viscodyne-D and placebo treatment groups in each trial. In a trial of 1 week duration in children 6 to 11 months of age patients who received oral Viscodyne-D exhibited greater irritability/fussiness than patients on placebo. In a trial of 18 months duration in patients 12 months and older, insomnia occurred more frequently in patients who received oral Viscodyne-D compared to patients who received placebo.

Viscodyne-D

The safety data of Viscodyne-D was evaluated in a randomized, double-blind, single-dose, non-inferiority study comparing Viscodyne-D to intravenous diphenhydramine in 262 adults with acute urticaria.

The adverse reactions with Viscodyne-D occurred at an incidence of less than 1% and include: dyspepsia, feeling hot, dysgeusia, headache, paresthesia, presyncope, and hyperhidrosis.

An additional randomized, double-blind, single dose study was conducted in 33 adults which showed similar safety results.

Sedation

Subject-rated sedation scores were assessed at baseline, 1 hr, and/or 2 hrs, and/or "Readiness for Discharge”. Sedation was rated on a 0 to 3 scale (0 = none, to 3 = severe) with lower sedation scores indicating less sedation. Subjects in the Viscodyne-D treatment group reported less sedation at all time points compared to subjects treated with diphenhydramine.

Viscodyne-D contraindications

See also:
What is the most important information I should know about Viscodyne-D?

The use of Viscodyne-D is contraindicated in patients with a known hypersensitivity to Viscodyne-D or any of its ingredients, levocetirizine, or hydroxyzine.

Active ingredient matches for Viscodyne-D:

Cetirizine Hydrochloride in India.

Dextromethorphan/Levocetirizine

Dextromethorphan hydrochloride/levocetirizine/zinc in India.

References

1. DailyMed. "DEXTROMETHORPHAN HYDROBROMIDE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
2. DailyMed. "CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
3. PubChem. "dextromethorphan". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).

Reviews

User reports

Consumer reviews

Information checked by Dr. Sachin Kumar, MD Pharmacology